Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.

Colin W Howden Shailja C ShahSalil N PendseElliot OffmanJune S Almenoff Kely L Sheldon

Published in: Alimentary pharmacology & therapeutics (2023)

PBPK modelling showed rifabutin 50 mg three times daily had higher intragastric exposure times than 150 mg once daily or twice daily, or 300 mg once daily. This low-dose rifabutin regimen provides the highest potential for H. pylori eradication while minimising systemic rifabutin exposure.

Keyphrases

helicobacter pylori infection
low dose
physical activity
helicobacter pylori
risk assessment
climate change